ArticleClinical kidney journal2026
Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endothelin Receptor Antagonists in Patients with IgA Nephropathy Treated with Sodium-Glucose Cotransporter 2 Inhibitors.Journal of the American Society of Nephrology : JASN · 2026Article
- Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sparsentan has emerged as a promising therapeutic option for immunoglobulin A nephropathy. However, data on its effectiveness in real-world settings, particularly in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors remain limited. In our previously published real-world cohort ( Methods: After 1 year, 17 patients (74%) from the initial cohort remained on sparsentan therapy. As described previously, patients had been on stable, maximally tolerated renin-angiotensin system (RAS) inhibition and stable SGLT2 inhibitor therapy before replacement of RAS inhibition with sparsentan; eligibility required an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m Results: Baseline median (interquartile range) eGFR (Chronic Kidney Disease Epidemiology Collaboration) was 48 ml/min/1.73 m Conclusions: In this 1-year follow-up of our real-world cohort, sparsentan was associated with a significant and sustained reduction in proteinuria over 12 months, with a numerically less steep eGFR decline during follow-up, even in patients already receiving SGLT2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.